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MaBACKGROUND Exosomes are nanometer-sized vesicles released from cells into the blood, where they can transmit
signals throughout the body. Shown to act on the heart, exosomes’ composition and the signaling pathways they activate
have not been explored. We hypothesized that endogenous plasma exosomes can communicate signals to the heart and
provide protection against ischemia and reperfusion injury.
OBJECTIVES This study sought to isolate and characterize exosomes from rats and healthy volunteers, evaluate their
cardioprotective actions, and identify the molecular mechanisms involved.
METHODS The exosome-rich fraction was isolated from the blood of adult rats and human volunteers and was analyzed
by protein marker expression, transmission electron microscopy, and nanoparticle tracking analysis. This was then used in
ex vivo, in vivo, and in vitro settings of ischemia-reperfusion, with the protective signaling pathways activated on
cardiomyocytes identiﬁed using Western blot analyses and chemical inhibitors.
RESULTS Exosomes exhibited the expected size and expressed marker proteins CD63, CD81, and heat shock protein
(HSP) 70. The exosome-rich fraction was powerfully cardioprotective in all tested models of cardiac ischemia-reperfusion
injury. We identiﬁed a pro-survival signaling pathway activated in cardiomyocytes involving toll-like receptor (TLR) 4 and
various kinases, leading to activation of the cardioprotective HSP27. Cardioprotection was prevented by a neutralizing
antibody against a conserved HSP70 epitope expressed on the exosome surface and by blocking TLR4 in cardiomyocytes,
identifying the HSP70/TLR4 communication axis as a critical component in exosome-mediated cardioprotection.
CONCLUSIONS Exosomes deliver endogenous protective signals to the myocardium by a pathway involving TLR4 and
classic cardioprotective HSPs. (J Am Coll Cardiol 2015;65:1525–36) © 2015 by the American College of Cardiology
Foundation.I n recent years, the potential for extracellular ves-icles to be used as therapeutic agents or as bio-markers of pathological states has generated
immense interest (1,2). Exosomes have been proposed
to stimulate beneﬁcial signaling pathways in cardio-
vascular disease (1), for example, potentially medi-
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ABBR EV I A T I ON S
AND ACRONYMS
HSP = heat shock protein
miRNA = microribonucleic acid
RIC = remote ischemic pre-
conditioning
TEM = transmission electron
microscopy
TLR = toll-like receptor
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1526which are present in the blood of humans and
rodents in the order of 1010 exosomes/ml (7).
These striking numbers raise crucial ques-
tions as to their role.SEE PAGE 1537Coronary artery obstruction produces myo-
cardial ischemia, which is usually treated with
myocardial reperfusion, although this para-
doxically causes further lethal injury thatcurrently lacks an effective clinical therapy (8). Heat
shock proteins (HSPs) are powerfully cardioprotective
(9–11), but clinical translation faltered without prac-
tical techniques for their induction or delivery. After
myocardial infarction, large elevations in serum HSP70
can stimulate inﬂammatory cytokine release via toll-
like receptor (TLR) 4 and the innate immune
response (12,13). However, a more mild stimulation of
innate immunity via TLR ligands is necessary for
myocardial pre-conditioning and cardioprotection
(14,15).
This raises the possibility that delivery of mode-
rate levels of HSP70 could be beneﬁcial. In addition
to these effects of circulating HSP70, other families
of HSP can mediate protection within the cell. For
example, the small HSP27 (HSPB1) is required for
optimal protection against ischemia and reperfusion
injury (16,17).
We hypothesized that endogenous exosomes
communicate signals to the heart to protect it against
ischemia and reperfusion injury. Furthermore,
because recent evidence suggests that microvesicles
can transfer protection by remote ischemic pre-
conditioning (RIC) (18), we hypothesized that RIC
would augment exosome production, thereby stimu-
lating cardioprotection. We puriﬁed, characterized,
and quantiﬁed exosomes from the plasma of rats and
humans, demonstrating protection against ischemia
and reperfusion both in vitro and in vivo. This
cardioprotection was mediated by HSP70 on exo-
somes, which activated a pathway downstream of
TLR4 involving extracellular signal-regulated protein
kinases (ERK) 1 and 2 and p38 mitogen-activated
protein kinase (MAPK), leading to phosphorylation
of HSP27.
METHODS
These studies used male Sprague Dawley rats treated
in accordance with the Animals (Scientiﬁc Procedures)
Act of 1986, published by the United Kingdom Home
Ofﬁce, and the Guide for the Care and Use of Labora-
tory Animals from the U.S. National Institutes of
Health (Publication No. 85-23, revised 1996).The study of human samples was performed
according to ethics approval reference 13/LO/0222
and Declaration of Helsinki principles. Exosomes
were isolated by centrifugation from healthy, 30- to
45-year-old male volunteers after written consent
and overnight fasting.
STATISTICAL ANALYSIS. Data are shown as mean 
SEM. Pairwise comparisons were made with the
Student t test. One-way analysis of variance was
followed by post-test analysis using the Tukey test for
multiple comparisons. Two-way analysis of variance
was carried out followed by Bonferroni correction to
test for signiﬁcance when performing multiple com-
parisons between different groups. A p value <0.05
was considered signiﬁcant.
Additional details of the materials and methods are
provided in the Online Appendix.
RESULTS
The exosome-rich fraction was puriﬁed from the
blood of adult male rats and healthy human male
volunteers using a standard protocol of serial, dif-
ferential centrifugation, and ultracentrifugation
steps. Using transmission electron microscopy (TEM),
we observed the typical “cup-shaped” vesicles of
exosomes that were <100 nm in diameter for both
rats and humans (Figure 1A).
We used nanoparticle tracking analysis to measure
the number and size distribution of particles in puri-
ﬁed, exosome-rich preparations; the modal size of
particles puriﬁed from control rat plasma was 75 
2 nm (Figures 1B and 1D), corresponding to the exo-
somes’ expected size, and the concentration was
0.1  0.02  1011 ml1 plasma (n ¼ 5 rats) (Figure 1C). In
human plasma, particle concentration was 6  3 
1011 ml1 (n ¼ 6) (Figure 1C), and average modal size
was 75  7 nm (Figure 1D). For simplicity, we refer
hereafter to the isolated particles as “exosomes,”
although the isolated fraction also included some
particles outside of the expected exosome size range.
Flow cytometry conﬁrmed the expression of
marker proteins for exosomes in the human samples.
The tetraspanin molecules CD63 and CD81 (found in
many exosomes), as well as HSP70, were all detect-
able at high levels (Figure 1E). Isotype control anti-
bodies were negative (Online Figure 1). Interestingly,
the positive signal obtained using antibody clone
cmHSP70.1, which speciﬁcally recognizes an epitope
of HSP70 expressed on the surface of cells and exo-
somes (19,20), suggested that HSP70 is exposed on
the surface of human exosomes (Figure 1E).
We also performed sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blot
FIGURE 1 Characterization and Quantiﬁcation of Plasma Exosomes
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(A) Electron micrographs of puriﬁed exosomes from rats and humans. Bar: 100 nm. (B) Representative results of nanoparticle tracking analysis (NTA) demonstrate similar
size distribution in diluted samples of human and rat exosomes. (C and D) Average concentration and size of exosomes in plasma (n ¼ 5 rats, n ¼ 6 humans). (E) Flow
cytometry analysis of microspheres coated with exosome-rich fractions isolated from humans identiﬁed the presence of exosomal markers CD63, CD81, and heat shock
protein (HSP) 70, both at baseline (control, blue), and after remote ischemic preconditioning (RIC) (salmon). Strong staining was also observed using antibody
cmHsp70.1. Yellow curve indicates exosome-coated microspheres stained with secondary antibodies (control). (F) Western blots conﬁrmed the presence of exosomal
marker proteins CD63, CD81, and HSP70 in human samples. Levels of all proteins were increased after RIC (*p < 0.05; n ¼ 3). (G) NTA demonstrates size distribution of
control and RIC exosomes. (H to J) The size distribution and concentration of human exosomes as determined by transmission electron microscopy (TEM) (H) and NTA (I),
before and after RIC. Average modal size of exosomes was unaltered by RIC (n ¼ 6). Plasma concentration of exosomes increased after RIC (**p < 0.01; n ¼ 6).
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FIGURE 2 Puriﬁed Plasma Exosomes Provide Cardioprotection
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(A) Exosomes puriﬁed from a control donor rat or a donor rat subject to RIC decreased infarct size (as percentage of area at risk [AAR]) in a naïve rat in an in vivo model of
reperfusion injury. Protection was similar when RIC was applied to the rat hind limb in vivo (in vivo RIC) (**p < 0.01; n ¼ 6). (B) Exosomes puriﬁed from a control rat, or 1
subject to RIC, decreased infarct size in an isolated, Langendorff-perfused rat heart model of reperfusion injury (**p < 0.01; n ¼ 6 to 9). (C) Flow cytometry analysis
shows that HL-1 cardiomyocytes were protected against hypoxia (Hypox) and reoxygenation (Reox) by pre-incubation with rat plasma exosomes, as determined by DiOC6
(3) and propidium iodide (PI) staining (n¼ 3). Insulin indicates positive control. (D) Pre-incubation with rat exosomes decreased death in primary adult rat cardiomyocytes
subject to hypoxia and reoxygenation. Representative images are shown from cells in conditions of normoxia, Hypox/Reox, with the addition of 109 exosomes/well,
or insulin as a positive control, as indicated; red indicates PI. A dose-response curve was performed with 105 to 109 control or RIC exosomes/well and compared with
insulin (Ins). (*p < 0.05; **p < 0.01 vs. Hypox/Reox alone; n ¼ 6). Bar: 100 mm. Abbreviations as in Figure 1.
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1528analyses to biochemically characterize the human
samples and were able to detect CD63, CD81, and
HSP70 (Figure 1F). Similar results were obtained using
rat exosomes (Online Figure 2).
To investigate whether plasma exosomes are car-
dioprotective, we used 4 different experimental
models. In an in vivo rat model, the entire exosome
fraction isolated from a donor rat was administered to
a naïve rat by intravenous tail vein injection 15 min
before occlusion of the left anterior descendingartery. The area at risk was the same in each group
(Online Figure 3A). The infarct size relative to the
area at risk was reduced from 48  5% (n ¼ 6) with
vehicle to 25  6% (p < 0.05; n ¼ 6) with exosomes
(Figure 2A). Second, to exclude the inﬂuence of blood,
Langendorff-perfused rat hearts were exposed to all
of the exosomes isolated from donor rat blood during
15-min perfusion, before being subjected to 35-min
ischemia followed by 2-h reperfusion. The area at
risk was the same in each group (Online Figure 3B).
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1529The size of the infarct relative to the area at risk was
signiﬁcantly reduced from 35  3% (n ¼ 6) to 22  2%
(p < 0.01; n ¼ 10) by pre-treatment with rat exosomes
(Figure 2B).
Next, we used 2 in vitro models of cardiac cells
to conduct simulated ischemia-reperfusion, termed
hypoxia-reoxygenation. Using the HL-1 cardio-
myocyte cell line and ﬂow cytometry, we analyzed
cell death using double staining with the vital dye
propidium iodide (PI) and the mitochondrial trans-
membrane potential (DJm)-sensitive dye DiOC6 (3).
After hypoxia-reoxygenation, 33  8% of the live cells
exhibited a low DJm—an early indicator of cell
death—compared with 6  4% in normoxia. The
population of PI-detected dead HL-1 cells was 45 
9% compared with 13  5% in normoxia (Figure 2C).
Pre-treatment with rat exosomes signiﬁcantly
increased healthy cells from 20  5% to 44  7% and
reduced the population of cells with low DJm (24 
5%) as well as the PIþve population of dead cells (30 
6%) (Figure 2C). Protection was similar to that
observed with insulin (27  5% low DJm, 31  5%
PIþve), which is known to be protective in this model
and was used as a positive control. These in vitro
results were conﬁrmed using primary adult rat car-
diomyocytes as a more physiological model of cardiac
cells and in a dose-response analysis. Hypoxia and
reoxygenation increased cardiomyocyte cell death
from 13  3% to 59  7% (p < 0.001; n ¼ 5) (Figure 2D).
The maximal tested dose of 109 exosomes/well was
highly cardioprotective, reducing cell death to 17 
3%, which is similar to the effect of insulin (14  3%),
and this protection remained down to a dose of 107
exosomes/well, at which exosomes decreased death
to 32  8% (Figure 2D).
If exosomes can activate cardioprotective path-
ways, this raises the possibility that manipulating
their levels in the blood might affect car-
dioprotection. No speciﬁc pharmacological inhibitors
have yet been developed for in vivo use to decrease
exosome production. However, it has recently been
proposed that brief cycles of hind limb ischemia and
reperfusion increase the number of extracellular
vesicles (both exosomes and microvesicles) in the
circulation (18). Such RIC also renders the heart in a
protected state (21,22).
We ﬁrst looked for any effect on plasma exosomes
in humans subject to RIC. Exosomes were isolated
from healthy volunteers both before and after a
standard RIC procedure and were characterized by
nanoparticle tracking analysis and TEM. RIC exo-
somes exhibited the same size and shape as control
exosomes (Figures 1G to 1J), but importantly, their
concentration in plasma was signiﬁcantly increasedafter RIC (Figure 1H). Exosome concentration was
similarly increased in rats after RIC (Online
Figure 4A).
The ability of exosomes from RIC-treated rats to
protect the heart was then determined. Administra-
tion of RIC exosomes signiﬁcantly decreased infarct
size, both in vivo (Figure 2A) and in vitro (Figure 2B).
We performed a complete dose-response curve
comparing exosomes from control and RIC rats, using
the in vitro model of hypoxia-reoxygenation on
primary cardiomyocytes. Although RIC exosomes
slightly increased protection, the difference was
nonsigniﬁcant (Figure 2D). This suggested that
although exosomes after RIC remain cardioprotective
and their numbers increase, this increase is insufﬁ-
cient to substantially affect cardioprotection in this
model.
We then studied the intracellular signaling path-
ways activated by exosomes on cardiac cells using
Western blot analysis. Adding rat exosomes to pri-
mary adult rat cardiomyocytes rapidly stimulated
cardioprotective kinases. Phosphorylation of ERK1/2
was elevated by 2 min and maximal after 5 min of
exosome exposure, decreasing by 15 min; how-
ever, there was no increase in protein kinase B
(AKT) phosphorylation after exosome treatment
(Figure 3A), despite its phosphorylation by insulin.
We saw a very similar time course of ERK1/2 phos-
phorylation with human exosomes, with maximal
phosphorylation after 5 min; again, no AKT phos-
phorylation was detected in response to exosomes at
any time point despite the insulin-caused dual acti-
vation of ERK1/2 and AKT (Figure 3B). These results
suggest that exosomes do not activate insulin-
receptor signaling. For further validation, we used
human exosomes to stimulate HL-1 cardiomyocytes
and again observed phosphorylation of ERK1/2 after
5 min without any AKT effect (Online Figure 5).
Activation of ERK1/2 was tested in response to exo-
somes puriﬁed from 4 different human volunteers; in
each case, exosomes signiﬁcantly stimulated ERK1/2
phosphorylation, by an average of 6.5  1.0-fold
(p < 0.05) (Figure 3C).
To unequivocally conﬁrm that ERK1/2 signaling
was involved in the cardioprotection conferred by
exosome treatment, cells were pre-incubated with
10 mM U0126 or 50 mM PD98059, inhibitors of ERK1/2
signaling at the level of MEK (MAPK/ERK kinase).
Both drugs completely inhibited ERK1/2 phosphory-
lation in response to human exosomes (Figure 3D)
as well as eliminated cardioprotection in adult
rat cardiomyocytes treated with human exosomes
(Figure 3E). In control experiments, the inhibitors
alone had no effect (Online Figure 6).
FIGURE 3 Activating the ERK1/2 Signaling Pathway
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(A) Western blot analysis of adult rat cardiomyocytes shows robust and rapid activation of extracellular signal-regulated protein kinases
1 and 2 (ERK1/2) after stimulation with rat plasma exosomes. Protein kinase B (AKT) was not activated (insulin indicates positive control; n ¼ 3
independent experiments). (B) Similarly, ERK1/2 but not AKT was phosphorylated in adult rat cardiomyocytes after exposure to human plasma
exosomes (n ¼ 3 independent experiments). (C) Human plasma exosomes isolated from 4 different individuals activated ERK1/2 phosphory-
lation after stimulation of adult rat cardiomyocytes for 5 min. (D) Pre-incubation (15 min) with the inhibitors of ERK1/2 phosphorylation, U0126
and PD98059, prevented ERK1/2 phosphorylation in adult rat cardiomyocytes stimulated with human exosomes for 5 min (n ¼ 3 independent
experiments). (E) In adult rat cardiomyocytes subjected to hypoxia/reoxygenation, U0126 and PD98059 blocked protection by human exo-
somes (n ¼ 3); *p < 0.05 and **p < 0.01 versus 0’ time point (A and B), versus control (C), or versus normoxia (E). Abbreviations as in Figure 2.
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1531One of the classic and highly cardioprotective
effector proteins is the small HSP27 (16), regulated by
phosphorylation at several serine residues. We tested
a panel of antibodies recognizing these phospho-
serine epitopes. Exposure of cardiomyocytes to
human exosomes increased phosphorylation of
HSP27 at all 3 sites relative to total levels of HSP27 or
when measured relative to a housekeeping protein
(Figure 4A). The clearest response was observed with
phosphorylation of Ser78; we subsequently used this
phosphorylation site to deﬁne the signaling pathway
leading to HSP27 phosphorylation.
We found that, in contrast to endothelial
cells, exosomes were not internalized by primary
cardiomyocytes (Online Figure 7), suggesting that
protection was mediated by a receptor-ligand inter-
action. Extracellular HSP70 is considered to be a
danger-associated molecular pattern, which can
activate immune responses by binding to TLR4
(13,23). Our ﬂow cytometry experiments suggested
that HSP70 is present on exosome surfaces. This
was conﬁrmed by immuno-gold labeling using
cmHsp70.1 and TEM of rat and human exosomes
(Figure 4B). To neutralize this exosomal HSP70, we
pre-incubated human exosomes with cmHSP70.1,
which decreased their ability to stimulate phos-
phorylation of both ERK1/2 and HSP27-Ser78
(Figure 4C). Furthermore, these exosomes were no
longer able to protect primary cardiomyocytes
against hypoxia and reoxygenation, and by itself,
the neutralizing antibody did not affect cell survival
(Figure 4D).
Upstream of HSP27 phosphorylation, 1 of the
most well-established activators is p38MAPK. Using
SB203580, an inhibitor of p38MAPKa/b, we observed
that HSP27 phosphorylation in response to exosomes
was blocked, whereas upstream ERK1/2 phosphory-
lation remained unaffected (Figure 5A). As discussed
earlier, U0126 blocked ERK1/2 phosphorylation, but
also prevented phosphorylation of HSP27 (Figure 5A).
These results suggest that ERK1/2 lies upstream of
p38MAPK in the pathway.
To establish a link between extracellular HSP70
and intracellular ERK1/2 and p38MAPK activation,
we used TAK-242 to block intracellular signaling from
TLR4. Pre-treatment with TAK-242 decreased ERK1/2
phosphorylation in response to exosomes and
blocked HSP27 phosphorylation (Figure 5A).
Finally, we studied the effect of the whole pathway
on the survival of cardiomyocytes subject to hypoxia-
reoxygenation. Blocking TLR4, ERK1/2, or p38MAPK
decreased the cardioprotective effect of exosome
treatment (Figure 5B).DISCUSSION
Previously considered to be extracellular debris,
exosomes are now understood to be vesicles com-
municating between cells. Evidence suggests that
exosomes from cultured stem cells are cardio-
protective (5,6); now, the present study has focused
on endogenous plasma exosomes. We found in vitro
and in vivo evidence that plasma exosomes are
cardioprotective in an acute setting, mediated
by exosomal HSP70 that stimulated TLR4 signaling,
and leading to the activation of ERK1/2, p38MAPK,
and subsequent HSP27 phosphorylation in cardio-
myocytes (Central Illustration).
The increase in exosome number stimulated by RIC
is interesting, but to date there are no tools available
to prevent exosome release in vivo; therefore,
rigorous exclusion of the role of exosomes in RIC
awaits the development of speciﬁc chemical in-
hibitors or knockout models. Alternatively, several
other candidate proteins that may mediate RIC have
been proposed, including stromal-derived factor-1a
(24) and interleukin-10 (25).
Despite great interest in the potential for exosomes
to deliver cargo inside of cells, we were unable to
detect any uptake of ﬂuorescently-labeled exosomes
into primary cardiomyocytes even after 24-h in-
cubation, despite their rapid uptake into endothelial
cells. Combined with the rapidity of the signaling
response and its dependence upon HSP70 and TLR4
signaling, this strongly suggests that cardioprotection
is mediated via direct ligand-receptor interaction on
the cell surface. Because exosomes also contain other
cargo such as miRNA, it will be interesting to deter-
mine whether they are capable of delivering longer-
term beneﬁt via known cardioprotective miRNAs (26).
The protein kinase signaling pathways important
for cardioprotection have been well described and
include ERK1/2 and/or PI3K/AKT (8). Exosomes did
not induce AKT, but rapidly activated ERK1/2 phos-
phorylation by 5 min; this was required to induce
cardioprotection. Potential downstream targets of
ERK1/2 include p38MAPK, which phosphorylates
HSP27 (27). Inhibition of ERK1/2 with U0126 or of
p38MAPK with SB203580 prevented phosphorylation
of HSP27 corresponding with the loss of protection.
SB203580 is speciﬁc to a and b isoforms of p38MAPK,
which are also the 2 isoforms that are protective when
transiently activated before ischemia (28).
One of the most well-characterized members of
the cardioprotective, small HSP family, HSP27 is
highly expressed in the myocardium (16). In addition
to controlling protein folding, small HSPs exert
FIGURE 4 Surface HSP70 Mediates ERK1/2 and HSP27 Phosphorylation
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**p < 0.01 versus control conditions. (B) Electron microscopy of rat exosomes immunostained with cmHsp70.1 demonstrates the presence of HSP70 on
exosomal surface both before and after RIC (black dots ¼ 5-nm gold particles). (C) Neutralization of exosomal HSP70 by cmHSP70.1 blocks the phos-
phorylation of ERK1/2 and HSP27-Ser78 in adult rat cardiomyocytes stimulated with exosomes for 5 min (n ¼ 3); **p < 0.01 over untreated cells; ##p < 0.01
over exosomes. (D) Neutralization of exosomal HSP70 by cmHSP70.1 blocks the protection of adult rat cardiomyocytes in response to exosomes.
Bar: 100 mm. Experiments are shown as mean  SEM, n ¼ 3; **p < 0.01. Abbreviations as in Figures 1 to 3.
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FIGURE 5 ERK- and p38MAPK-Dependent Induction of HSP27
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1533powerful protection against oxidative stress and
apoptosis and maintain sarcomeric structure (16,17).
Strikingly, despite being well-characterized and
strongly activated in response to heat stress, no
practical method of stimulating HSP27 phosphoryla-
tion has been developed and translated to the clinic.
Our study shows for the ﬁrst time to our knowledge
that endogenous plasma exosomes can activate
this HSP.We previously developed a neutralizing antibody
against the highly-conserved, exposed C-terminal
of HSP70 (19), demonstrating that it blocks the
immunosuppressive signaling pathways stimulated
by exosomal HSP70 in myeloid-derived suppressor
cells (20). We show here that neutralizing HSP70 on
exosomes prevents their protective actions in car-
diomyocytes. Heat shock proteins, including HSP27
and HSP70, are intracellular chaperones important for
CENTRAL ILLUSTRATION Exosome-Stimulated Cardioprotection
The proposed mechanism of action by which exosomes communicate cardioprotective signals to the heart is mediated by heat shock protein (HSP) 70 on
exosomes. This activates a pathway downstream of toll-like receptor 4 (TLR) involving extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) and
p38 mitogen-activated protein kinase (p38MAPK), leading to phosphorylation of HSP27.
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1534correct protein homeostasis. HSP70 is secreted from
cells by exosomes (20) and is present in the serum
of healthy individuals (29). Beyond HSP70’s well-
established intracellular protective role, an intrigu-
ing new, extracellular role is emerging for HSP70 (30).
For instance, supporting cells in the inner ear can
secrete HSP70 to protect hair cells from cell death in
response to ototoxic drugs (31). Plasma HSP70 is
believed to play a role in activating the adaptive and
innate immune response (32). Although activating
the innate immune system is generally considered
to be detrimental to the heart, a small degree ofactivation is protective (15); this is highly reminiscent
of the manner in which sublethal episodes of ische-
mia are protective during ischemic pre-conditioning.
Importantly, mice lacking TLR4 appear resistant
to the beneﬁcial effects of pre-conditioning (14,15).
Our data suggest that exosomal HSP70 can
activate protective pathways in cardiomyocytes via
TLR4, part of the ancient, innate immune system
response.
STUDY LIMITATIONS. It is not currently possible to
achieve complete purity of exosomes from plasma,
and consequently, signiﬁcant amount of proteins and
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Exosomes are
nanometer-sized vesicles released from cells into the blood.
Exosome-rich extracts from plasma activate signaling pathways
that can protect against experimental ischemia-induced injury in
cardiac myocytes.
TRANSLATIONAL OUTLOOK: Further work is required to
develop simpler methods to isolate and purify exosomes, to
understand the pathways regulating their release and distribu-
tion, and to explore the potential therapeutic value of the
endogenous protective mechanisms they activate.
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1535protein aggregates may still be present in the isolated
fraction. We performed TEM to conﬁrm the presence
of HSP70 on the exosomal surface and conﬁrmed the
lack of signiﬁcant endotoxin contamination, but we
cannot exclude that nonexosomal HSP70 may be
involved, or that other known inducers of TLRs are
present. Because TAK-242 did not entirely block
ERK1/2 phosphorylation by exosomes, it is possible
that either TLR4 was incompletely inhibited by
TAK-242 or ERK1/2 can be partially activated by an
alternative, parallel route such as TLR2. Furthermore,
because exosome isolation from biological ﬂuids is
challenging, accurate direct measurement of plasma
exosome concentration before and after RIC awaits
improved technology. We did not quantify the in-
crease in exosome concentration in animals after
exosome administration to conﬁrm a mass-action ef-
fect of exosomes. Because a larger quantity of blood
was used to isolate exosomes from humans than rats,
and an additional ultracentrifugation step was
included to obtain an exosome fraction of comparable
purity, we could not directly compare rat and human
exosomes. All samples were compared to vehicle,
which could potentially have inﬂuenced results.
CONCLUSIONS
Given that plasma exosomes are cardioprotective,
these nanoparticles are worthy of further investigationin our search for ways to protect the myocardium at
risk of severe injury.
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